Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Behavioral Neurology & Neuropsychiatry
How does the microbiome factor into neurodegenerative diseases?
Related Questions
What would prompt discontinuing treatment versus switching or sequencing treatment in patients treated with an anti-amyloid therapy for Alzheimer's?
How do you approach an isolated increased protein levels in the CSF in patients with cognitive decline?
How does APOE4 status affect your clinical decision-making in patients who may be eligible for anti-amyloid therapies for early Alzheimer's disease?
Do you use amyloid lowering therapy in patients on chronic anticoagulation?
When is the most appropriate time to initiate evaluation for learning disorders following traumatic brain injury in an adolescent?
What are the best practices for centers interested in providing anti-amyloid therapies for early Alzheimer's to ensure treatment delivery success?
When do you consider using stimulants in patients with cognitive impairments secondary to traumatic brain injury?
Is a history of coronary artery disease and afib a contraindication to using donepezil?
What is your approach to patients who develop ARIA-E or ARIA-H during treatment with anti-amyloid therapies?
How do you treat extrapyramidal symptoms secondary to anti-psychotic use in patients who have not benefited from cogentin or benadryl?
